: Prot #BIA 28‐6156‐201: A Phase 2, Randomized, Double‐Blind, Placebo‐Controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28‐6156 in Subjects With Parkinson’s Disease With a Pathogenic Variant i